Artificial Intelligence
POET Technologies Named to 2022 OTCQX Best 50
TORONTO, Jan. 24, 2022 (GLOBE NEWSWIRE) — POET Technologies Inc. (“POET” or the “Company”) (TSX Venture: PTK; OTCQX: POETF), the designer and developer of the POET Optical Interposer™ and Photonic Integrated Circuits (PICs) for the data center and tele-communication markets, today announced the Company has been named to the 2022 OTCQX® Best 50, a ranking of top performing companies traded on the OTCQX Best Market last year.
The OTCQX Best 50 is an annual ranking of the top 50 U.S. and international companies traded on the OTCQX market. The ranking is calculated based on an equal weighting of one-year total return and average daily dollar volume growth in the previous calendar year. Companies in the 2022 OTCQX Best 50 were ranked based on their performance in 2021.
POET’s Executive Vice President and CFO, Thomas Mika, commented, “It’s rewarding to be recognized as one of the top performing OTCQX companies in 2021. During the past year, the Company made significant commercial progress and achieved a number of milestones, including the introduction and demonstrations of multiple new products based on POET’s Optical Interposer Platform, the shipment of samples to customers as well as the securing of initial design wins and purchase orders. Additionally, we successfully established collaborative development and supply agreements with key industry partners, and the Company meaningfully improved its cash position. We look forward to extending the Company’s growing momentum in 2022 as we continue to execute on the commercial ramp of POET’s technology.”
For the complete 2022 OTCQX Best 50 ranking, visit:
https://www.otcmarkets.com/files/2022_OTCQX_Best_50.pdf.
The OTCQX Best Market offers transparent and efficient trading of established, investor-focused U.S. and global companies. To qualify for the OTCQX market, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with applicable securities laws.
About POET Technologies Inc.
POET Technologies is a design and development company offering integration solutions based on the POET Optical Interposer™, a novel platform that allows the seamless integration of electronic and photonic devices into a single multi-chip module using advanced wafer-level semiconductor manufacturing techniques and packaging methods. POET’s Optical Interposer eliminates costly components and labor-intensive assembly, alignment, burn-in and testing methods employed in conventional photonics. The cost-efficient integration scheme and scalability of the POET Optical Interposer brings value to any device or system that integrates electronics and photonics, including some of the highest growth areas of computing, such as Artificial Intelligence (AI), the Internet of Things (IoT), autonomous vehicles and high-speed networking for cloud service providers and data centers. POET is headquartered in Toronto, with operations in Allentown, PA, Shenzhen, China and Singapore. More information may be obtained at www.poet-technologies.com.
This news release contains “forward-looking information” (within the meaning of applicable Canadian securities laws) and “forward-looking statements” (within the meaning of the U.S. Private Securities Litigation Reform Act of 1995). Such statements or information are identified with words such as “anticipate”, “believe”, “expect”, “plan”, “intend”, “potential”, “estimate”, “propose”, “project”, “outlook”, “foresee” or similar words suggesting future outcomes or statements regarding any potential outcome. Such statements include the Company’s expectations with respect to the success of the Company’s product development efforts, the performance of its products, the expected results of its operations, meeting revenue targets, and the expectation of continued success in the financing efforts, the capability, functionality, performance and cost of the Company’s technology as well as the market acceptance, inclusion and timing of the Company’s technology in current and future products.
Such forward-looking information or statements are based on a number of risks, uncertainties and assumptions which may cause actual results or other expectations to differ materially from those anticipated and which may prove to be incorrect. Assumptions have been made regarding, among other things, management’s expectations regarding the success and timing for completion of its development efforts, financing activities, future growth, recruitment of personnel, opening of offices, the form and potential of its joint venture, plans for and completion of projects by the Company’s third-party consultants, contractors and partners, availability of capital, and the necessity to incur capital and other expenditures. Actual results could differ materially due to a number of factors, including, without limitation, the failure of its products to meet performance requirements, lack of sales in its products, once released, operational risks in the completion of the Company’s anticipated projects, lack of performance of its joint venture, delays in recruitment for its newly opened operations or changes in plans with respect to the development of the Company’s anticipated projects by third-parties, risks affecting the Company’s ability to execute projects, the ability of the Company to generate sales for its products, the ability to attract key personnel, and the ability to raise additional capital. Although the Company believes that the expectations reflected in the forward-looking information or statements are reasonable, prospective investors in the Company’s securities should not place undue reliance on forward-looking statements because the Company can provide no assurance that such expectations will prove to be correct. Forward-looking information and statements contained in this news release are as of the date of this news release and the Company assumes no obligation to update or revise this forward-looking information and statements except as required by law.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
120 Eglinton Avenue, East, Suite 1107, Toronto, ON, M4P 1E2- Tel: 416-368-9411 – Fax: 416-322-5075
Artificial Intelligence
Praesidiad takes High Court action against competitor and ex-employees for alleged wrongdoing
LONDON, May 7, 2024 /PRNewswire/ — Through its subsidiary, Hesco Bastion Limited (Hesco), legal action has been commenced in the High Court in London against Dirickx Systems Limited (Dirickx) and a number of ex-employees of Hesco. The claim involves allegations of misuse of confidential information, breach of employee’s duties of good faith, infringement of patent and copyright as well as misrepresentations to customers.
The allegations of wrongdoing include the removal by the ex-employees, either alone or together, of commercially sensitive information, confidential to Hesco.
Hesco is seeking orders from High Court for appropriate injunctions to restrain further infringing activity, an enquiry into damages or alternatively an account of Dirickx’s profits as well as payment of its legal costs. A High Court trial in London is expected within 12-18 months.
Dino Koutrouki, CEO, said “Whilst Praesidiad as a business welcomes legitimate competition, it is not prepared to allow the actions of former employees, placed in a position of trust and duty of good faith, to unlawfully take advantage of the foundations of our business in order compete with us.
Hesco has a proud history as a leading innovator. For over 30 years customers have depended on us for original, high quality life safety products conceived, created and developed by us and tested independently to the highest standards. We have a duty to defend our innovation and our brand through this High Court action. Hesco intends to pursue its claims to the fullest degree, and we confidently expect the litigation process will reveal the full extent of wrongdoing of which the above is only a snapshot.”
Full details of our claim can be viewed on our website and here: Particulars_of_Infringement
Particulars_of_Claim
About Praesidiad
PRÆSIDIAD (www.praesidiad.com) owned brands Betafence and Hesco are market leaders in integrated perimeter and physical security solutions. Global Manufacturers of fencing products, defensive barriers, body armor and industrial mesh; manufacturing and supplying protection around the world.
About HESCO
Hesco (www.hesco.com) is a world leader and innovator in defence, perimeter protection and security systems, including defensive barriers, flood barriers, rapid deployment systems, safe haven bunkers and ballistic resistant body armor.
Hesco is synonymous with force protection and is recognised across its industry for its commitment to saving lives, property and the environment, whenever and wherever it is needed.
Photo – https://mma.prnewswire.com/media/2403823/HESCO.jpg
View original content:https://www.prnewswire.co.uk/news-releases/praesidiad-takes-high-court-action-against-competitor-and-ex-employees-for-alleged-wrongdoing-302134886.html
AMSTERDAM, May 7, 2024 /PRNewswire/ — In a move that underscores its innovation in smart cleaning technology, Pudu Robotics (“PUDU”), the global leader in service robotics, is set to captivate the cleaning industry with its first appearance at the prestigious Interclean Amsterdam 2024, the largest professional cleaning trade show in the world and unsurpassed in its role as an international business networking platform for the cleaning and hygiene industry.
From May 14-17, PUDU’s booth in Hall 5 05.317 at RAI Amsterdam will serve as a beacon for innovation, inviting industry professionals to explore the new cleaning frontier, where they will have the exclusive opportunity to witness cutting-edge advancements in cleaning technology.
The spotlight of this year’s showcase is undoubtedly on the official debut of the highly anticipated and newly upgraded PUDU SH1, a smart upright scrubber dryer that is set to redefine cleaning efficiency and effectiveness. Scheduled for May 14th between 14:00-15:00, an unveiling ceremony will introduce attendees to this next-generation cleaner. This event will include insightful presentations from product experts detailing key upgrades of PUDU SH1 and an overview of new solutions provided by its counterpart, PUDU CC1.
In addition to product introductions, visitors are encouraged to engage with live demonstrations taking place at the Robot Arena throughout the exhibition days.
PUDU’s Daily Demonstration Schedule at the Robot Arena
– Tuesday, May 14: Sessions at 10:45, 12:30, 14:15, and 16:00- Wednesday, May 15: Sessions at 11:15, 13:00, 14:45, and 16:30- Thursday, May 16: Sessions at 10:15, 12:00, 13:45, 15:30 and 17:15- Friday, May 17: Session at 11:30
These sessions offer a hands-on experience with PUDU CC1 while facilitating direct interaction with specialists who can provide deeper insights into their operational capabilities and benefits.
PUDU is enthusiastic about engaging with fellow innovators and stakeholders who are keen on developing future clean environments through intelligent technology. By showcasing its technological prowess and commitment to advancing smart cleaning solutions, PUDU aims to showcase new products, foster industry connections and seek potential partnerships at Interclean Amsterdam 2024.
To learn more about the latest information on cleaning products and to gain an immersive experience, visitors can register through the following link to obtain FREE tickets from PUDU:
https://register.visitcloud.com/survey/2hdir9zqg5391?actioncode=NTWO001675WTZ&partner-contact=03bjh516im8tu
About Pudu Robotics
Pudu Robotics, a global leader in the service robotics sector, is dedicated to enhancing human productivity and living standards through innovative robot technology. With a focus on R&D, manufacturing, and sales of service robots, Pudu Robotics holds nearly a thousand authorized patents worldwide, encompassing a wide range of core technologies. The company’s robots have been widely adopted in various industries, including dining, retail, hospitality, healthcare, entertainment, education, and manufacturing. To date, Pudu Robotics has successfully shipped over 70,000 units to a variety of markets, with a presence in more than 60 countries and regions worldwide.
For more information on business developments and updates, follow PUDU on Facebook, YouTube, LinkedIn, Twitter, and Instagram.
Photo – https://mma.prnewswire.com/media/2406274/Pudu_Robotics_takes_part_Interclean_Amsterdam_2024.jpgLogo – https://mma.prnewswire.com/media/2193118/Pudu_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/pudu-robotics-debuts-advanced-smart-cleaning-tech-at-interclean-amsterdam-302137623.html
Artificial Intelligence
Clarivate Introduces Epidemiology Intelligence™ for Precision Patient Population Analysis
Empowering biopharma with unified epidemiology, incidence and prevalence data alongside claims-based population insights, for precise market sizing and patient population analysis
LONDON, May 7, 2024 /PRNewswire/ — Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced the launch of Epidemiology Intelligence™. The new solution combines rich insights from epidemiology, incidence and prevalence database solutions. It includes U.S. claims-based population insights to empower biopharma companies to accurately gauge market size and target patient demographics with ease.
In today’s rapidly evolving market landscape, precise forecasting is essential for biopharmaceutical companies. Yet, traditional research methods often come with limitations that can lead to inaccurate estimations and costly consequences. Epidemiology Intelligence empowers users with unique insights to address critical questions about the drug-treatable population. The solution facilitates precise assessments, identification of niche populations and accurate predictions based on population insights.
Ravindra Sharma, VP Product Management, Clarivate, said: “The launch of Epidemiology Intelligence marks a significant milestone for Clarivate in our ongoing commitment to deliver comprehensive and actionable solutions to life sciences and healthcare companies. Clients can now access comprehensive coverage of disease epidemiology paired with expert analysis, seamlessly integrated into a unified platform. The new solution enables them to deliver safe, effective and commercially successful treatments to patients faster.”
Epidemiology Intelligence accelerates data-driven decision-making across the drug development lifecycle. Clients can benchmark market forecasts, validate investments, pinpoint growth opportunities and utilize the solution to strategically position their products for success.
To learn more about Epidemiology Intelligence, visit here.
About Epidemiology Intelligence
Epidemiology Intelligence is a new, unified Clarivate patient population offering that brings together our legacy Epidemiology and Incidence and Prevalence Database solutions, as well as claims-based population insights, on a single platform. This transformative solution offers user-friendly visualizations, easy data exports and a unique breadth and depth of patient population insights. Conduct thorough market assessment with comprehensive coverage across 1200+ diseases and procedures. Dive deep into expert disease-specific epidemiology analysis and 10 and 20-year forecasts across 220 indications and over 5000 patient populations. Leverage expanded patient segmentation and location granularity with insights sourced from Clarivate U.S. Real-World Data.
About ClarivateClarivate™ is a leading global provider of transformative intelligence. We offer enriched data, insights & analytics, workflow solutions and expert services in the areas of Academia & Government, Intellectual Property and Life Sciences & Healthcare. For more information, please visit www.clarivate.com
Media Contact:Catherine DanielDirector External Communications, Life Sciences & [email protected]
Logo – https://mma.prnewswire.com/media/1159266/Clarivate_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/clarivate-introduces-epidemiology-intelligence-for-precision-patient-population-analysis-302136896.html
-
Artificial Intelligence4 days agoCleverTap launches Clever.AI, the AI-Driven Edge for Customer Engagement & Retention
-
Uncategorized4 days agoImproving the Developer Journey in Crafting Artificial Intelligence Applications
-
Artificial Intelligence6 days agoAppdome Unveils World’s First Agentless Mobile EDR & MTD
-
Uncategorized4 days ago
Unveiling the Complex Psychological Implications of Artificial Intelligence
-
Artificial Intelligence4 days ago5G Enterprise Market Projected to Reach $115.81 billion by 2030 – Exclusive Report by 360iResearch
-
Artificial Intelligence4 days agoBitrue expands Bitcoin Runes Offerings with GPTV Listing and Staking Options
-
Artificial Intelligence4 days agoAppian Named a Leader in the 2024 Gartner® Magic Quadrant™ for Process Mining Platforms Report
-
Artificial Intelligence4 days agoInnodisk Introduces iCAP Air: Advancing Air Quality Management through Autonomous Decision-Making
